The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Effects of IL-17A Inhibitors on the Microbiota

The Effects of IL-17A Inhibitors on the Microbiota

February 16, 2021 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Additional Perspective

Joerg Ermann, MD, a rheumatologist with Brigham and Women’s Hospital, Boston, found the research important because it emphasizes the bi-directional relationship between intestinal microbiota and the human immune system. The study would have been stronger with a larger sample size and better matched experimental groups, he says. 

You Might Also Like
  • Research Suggests Th17 Cells Have Microbiota-Dependent Role in RA
  • Fungal Microbiota Dysbiosis Seen in Inflammatory Bowel Disease
  • The Microbiome’s Role in Inflammatory Arthritis
Explore This Issue
February 2021
Also By This Author
  • Flare Risk Increases When Medication Is Stopped Prior to Arthroplasty

“I think this is an interesting research direction, but results need to be confirmed with a bigger study and subjects randomized to the different treatments. Ideally, one would tag on fecal sample collection to clinical trials,” Dr. Ermann says. He does not think the research into gut microbiota findings is currently of major interest to pharmaceutical companies developing drugs for spondyloarthritis. However, this might change under the influence of studies like the one by Manasson et al.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The field needs a better understanding of who will respond to a specific therapy and who might develop inflammatory bowel disease or other side effects. The analysis of fecal microbiota is a promising approach to the development of much needed biomarkers.


Vanessa Caceres is a medical writer in Bradenton, Fla.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Manasson J, Coras R, Guma M. Interleukin-17 inhibition in spondyloarthritis is associated with subclinical gut microbiome perturbations and a distinctive interleukin-25-driven intestinal inflammation. Arthritis Rheumatol. 2020 Apr;72(4):645–657.
  2. Busquets D, Mas-de-Xaxars T, Lopez-Siles M, et al. Anti-tumour necrosis factor treatment with adalimumab induces changes in the microbiota of Crohn’s disease. J Crohns Colitis. 2015 Oct;9(10):899–906.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Research Reviews, Spondyloarthritis Tagged With: gut microbiota, Microbiome, PsA Resource Center, Psoriatic Arthritis, secukinumabIssue: February 2021

You Might Also Like:
  • Research Suggests Th17 Cells Have Microbiota-Dependent Role in RA
  • Fungal Microbiota Dysbiosis Seen in Inflammatory Bowel Disease
  • The Microbiome’s Role in Inflammatory Arthritis
  • Gut Microbiota Directly Affects Inflammatory Arthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)